Within Novo Nordisk's comprehensive business update to investors, attention latched onto early data for an oral obesity therapy that outperformed the company’s big-selling GLP-1 agonist Wegovy ...

Information provided on Forbes Advisor is for educational purposes only. Your financial situation is unique and the products and services we review may not be right for your circumstances.

Novo Nordisk's obesity therapy Wegovy put in another strong sales performance ... As a result of the pressure on its GLP-1 agonist franchise, the Danish group is now predicting a slight slowdown ...

Information provided on Forbes Advisor is for educational purposes only. Your financial situation is unique and the products and services we review may not be right for your circumstances.

'ZDNET Recommends': What exactly does it mean? ZDNET's recommendations are based on many hours of testing, research, and comparison shopping. We gather data from the best available sources ...

Citing rising costs, health insurers in the Philadelphia region and around the country are dropping or restricting coverage for some medications in this newer class of drugs, known as GLP-1 agonists.